8-K: Merus N.V. Acquisition by Genmab Finalized, Shares Delisted

Genmab A/S has completed its acquisition of Merus N.V. for $97.00 per share, leading to the delisting of Merus's common shares from Nasdaq.

Summary

• Merus N.V. has completed its acquisition by Genmab A/S and its subsidiary Genmab Holding II B.V.
• The acquisition was for $97.00 per Common Share in cash.
• By the initial offer expiration on December 11, 2025, approximately 94.2% (71,463,077 shares) of Merus's shares were validly tendered.
• Following a subsequent offering period that ended on December 29, 2025, a total of approximately 97.39% (73,884,293 shares) were validly tendered.
• The Back-End Merger and Back-End Cancellation were effective on December 29, 2025, resulting in all remaining common shares being cancelled and converted into the right to receive the offer consideration.
• A Dutch dividend withholding tax of $10.67 per share will be deducted from the consideration for minority shareholders.
• Merus N.V. common shares were delisted from Nasdaq, with trading halted on the evening of December 29, 2025, and ceasing prior to the opening of trading on December 30, 2025.
• The company will proceed with deregistration from the SEC and suspension of reporting obligations.

Sentiment

Score: 7

Explanation: The filing confirms the successful completion of a previously announced acquisition, providing a definitive cash exit for shareholders. While the delisting and tax deduction are noted, the overall sentiment is positive for shareholders who accepted the offer, as the transaction proceeded as expected without delays or negative surprises beyond the known tax implications.

Positives

• Shareholders who tendered their shares received $97.00 per Common Share in cash, representing a definitive value for their investment.
• The acquisition provides a clear exit strategy and liquidity for Merus N.V. shareholders.

Negatives

• Minority shareholders will have a Dutch dividend withholding tax of $10.67 per share deducted from their cash consideration.
• Merus N.V. common shares have been delisted from Nasdaq, removing public trading access.
• The company will cease to be a publicly traded entity, ending its independent operations and reporting obligations.

Risks

• Minority shareholders face a mandatory deduction of $10.67 per share for Dutch dividend withholding tax, reducing their net proceeds.
• Shareholders who did not tender their shares during the offer periods had their shares cancelled and converted into cash, losing any potential future upside from Merus N.V. as an independent entity.

Future Outlook

Merus N.V. will cease to be a publicly traded company, with its common shares delisted from Nasdaq and its reporting obligations to the SEC suspended. The company will operate as a wholly-owned subsidiary of Genmab A/S.

Management Comments

• Jan G. J. van de Winkel, Chief Executive Officer, signed the report on behalf of Merus N.V. on December 30, 2025.

Industry Context

This acquisition represents a consolidation within the biotechnology or pharmaceutical sector, where larger companies often acquire smaller, innovative firms to expand their pipeline or technology base. Genmab A/S, a prominent player in antibody therapeutics, has successfully integrated Merus N.V., known for its bispecific antibody technology, which could enhance Genmab's competitive position in oncology and other therapeutic areas.

Comparison to Industry Standards

• The acquisition price of $97.00 per share provides a specific valuation for Merus N.V., which can be compared to recent M&A transactions in the biotechnology sector, such as Pfizer's acquisition of Seagen for $43 billion or AbbVie's acquisition of ImmunoGen for $10.1 billion, on a per-share or enterprise value basis relative to pipeline assets and market capitalization.
• The high tender rate of 97.39% indicates strong shareholder acceptance, which is typical for all-cash offers at a premium, similar to the shareholder response seen in the acquisition of Arena Pharmaceuticals by Pfizer.
• The use of a 'Back-End Merger' and 'Back-End Cancellation' to squeeze out remaining minority shareholders is a standard practice in Dutch corporate law for achieving 100% ownership after a successful tender offer, mirroring mechanisms used in other European cross-border acquisitions.
• The deduction of Dutch dividend withholding tax is a standard tax implication for non-Dutch resident shareholders in such transactions involving Dutch companies, comparable to tax considerations in other international M&A deals.

Management Changes

Stakeholder Impact

• Shareholders: Received $97.00 per share in cash, less $10.67 Dutch dividend withholding tax for minority shareholders. Shares are no longer publicly traded.
• Employees: Not explicitly mentioned, but typically, employees of an acquired company may experience changes in management, benefits, or corporate culture.
• Customers/Suppliers: Not explicitly mentioned, but the acquisition by Genmab A/S could lead to integration of operations, potentially affecting existing relationships.

Next Steps

• Purchaser intends to cause Merus N.V. to file Form 25 with the SEC to delist and deregister common shares under Section 12(b) of the Exchange Act.
• After Form 25 becomes effective, Purchaser intends to cause Merus N.V. to file Form 15 to terminate registration and suspend reporting obligations to the SEC.
• The Paying Agent will deduct and remit Dutch dividend withholding tax amounts to the Dutch tax authority.

Key Dates

Recommendation

For any remaining shareholders, the recommendation is to 'sell' or rather, acknowledge the mandatory conversion of shares into cash. With the completion of the acquisition, delisting from Nasdaq, and the Back-End Merger/Cancellation, Merus N.V. shares no longer exist as publicly tradable securities. Shareholders will receive the predetermined cash consideration of $97.00 per share (less applicable taxes), effectively liquidating their investment in Merus N.V. as an independent entity. There is no further investment opportunity in Merus N.V. common shares.

Keywords

Merus N.V., Genmab A/S, Acquisition, Tender Offer, Delisting, Biotechnology, Pharmaceuticals, Merger, SEC Filing, MRUS, Nasdaq